
Exelixis EXEL
$ 44.29
0.68%
Annual report 2026
added 02-10-2026
Exelixis Cash Conversion Cycle 2011-2026 | EXEL
Annual Cash Conversion Cycle Exelixis
| 2026 | 2025 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.32 | - | 5.31 | 68.5 | 66.8 | 14.4 | 59.3 | 61.7 | -5.2 | -355 | -304 | -649 | -2.06 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 68.5 | -2.06 K | -259 |
Quarterly Cash Conversion Cycle Exelixis
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45.3 | -1.54 | -35.5 | - | -65.7 | 12 | 5.34 | - | 49.3 | 45.1 | 43.4 | - | 77.3 | 128 | 110 | 78.1 | 81.3 | 88.8 | 92.4 | 54.1 | -53.6 | 83 | 28.1 | - | 75.7 | 41.8 | 53.2 | 65 | 52.7 | 63.6 | 5.03 | 38.2 | -6.26 | 74.8 | 68.6 | 77.4 | 96.6 | 102 | 135 | 47.6 | 48 | 59.2 | 48.9 | 60.6 | 70.8 | 67.9 | 82.1 | 82.7 | 65.8 | 30.3 | 31.6 | 32.1 | 18.9 | 32.1 | 6.78 | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 135 | -65.7 | 50.9 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | ||
|
Amgen
AMGN
|
217 | $ 345.82 | 1.71 % | $ 186 B | ||
|
Amneal Pharmaceuticals
AMRX
|
117 | $ 12.61 | 2.35 % | $ 3.95 B | ||
|
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | ||
|
Arcutis Biotherapeutics
ARQT
|
158 | $ 24.35 | 4.64 % | $ 3.1 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
-58 | - | - | $ 96.9 B | ||
|
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | ||
|
Autolus Therapeutics plc
AUTL
|
119 | $ 1.44 | 5.51 % | $ 383 M | ||
|
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B | ||
|
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | ||
|
Aytu BioScience
AYTU
|
174 | $ 2.74 | 6.42 % | $ 17.2 M | ||
|
Avid Bioservices
CDMO
|
85.5 | - | - | $ 789 M | ||
|
Cidara Therapeutics
CDTX
|
2.26 K | - | - | $ 1.41 B | ||
|
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - | ||
|
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | ||
|
Cerus Corporation
CERS
|
47 | $ 1.94 | 5.43 % | $ 370 M | ||
|
CTI BioPharma Corp.
CTIC
|
-216 | - | - | $ 1.2 B | ||
|
AIkido Pharma
AIKI
|
-1.92 | - | 1.93 % | $ 17.4 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
-1.6 K | - | -4.36 % | $ 27 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
-101 | - | - | $ 2.18 B | ||
|
Dynavax Technologies Corporation
DVAX
|
459 | - | - | $ 2.02 B | ||
|
Coherus BioSciences
CHRS
|
149 | $ 1.68 | 0.6 % | $ 197 M |